Literature DB >> 34687129

Tryptophan and its metabolites in normal physiology and cancer etiology.

Lizbeth Perez-Castro1, Roy Garcia1, Niranjan Venkateswaran1, Spencer Barnes2, Maralice Conacci-Sorrell1,3,4.   

Abstract

Within the growing field of amino acid metabolism, tryptophan (Trp) catabolism is an area of increasing interest. Trp is essential for protein synthesis, and its metabolism gives rise to biologically active catabolites including serotonin and numerous metabolites in the kynurenine (Kyn) pathway. In normal tissues, the production of Trp metabolites is directly regulated by the tissue-specific expression of Trp-metabolizing enzymes. Alterations of these enzymes in cancers can shift the balance and lead to an increased production of specific byproducts that can function as oncometabolites. For example, increased expression of the enzyme indoleamine 2,3-dioxygenase, which converts Trp into Kyn, leads to an increase in Kyn levels in numerous cancers. Kyn functions as an oncometabolite in cancer cells by promoting the activity of the transcription factor aryl hydrocarbon receptor, which regulates progrowth genes. Moreover, Kyn also inhibits T-cell activity and thus allows cancer cells to evade clearance by the immune system. Therefore, targeting the Kyn pathway has become a therapeutic focus as a novel means to abrogate tumor growth and immune resistance. This review summarizes the biological role and regulation of Trp metabolism and its catabolites with an emphasis on tumor cell growth and immune evasion and outlines areas for future research focus.
© 2021 Federation of European Biochemical Societies.

Entities:  

Keywords:  AHR; IDO1; TDO2; cancer; immune evasion; kynurenine; proliferation; tryptophan

Year:  2021        PMID: 34687129     DOI: 10.1111/febs.16245

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  5 in total

1.  Critical Assessment of a Structure-Based Screening Campaign for IDO1 Inhibitors: Tips and Pitfalls.

Authors:  Andrea Mammoli; Elisa Bianconi; Luana Ruta; Alessandra Riccio; Carlo Bigiotti; Maria Souma; Andrea Carotti; Sofia Rossini; Chiara Suvieri; Maria Teresa Pallotta; Ursula Grohmann; Emidio Camaioni; Antonio Macchiarulo
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

2.  Tryptophan 2,3-dioxygenase may be a potential prognostic biomarker and immunotherapy target in cancer: A meta-analysis and bioinformatics analysis.

Authors:  Yanyan Hu; Zhongjian Liu; Hui Tang
Journal:  Front Oncol       Date:  2022-10-03       Impact factor: 5.738

3.  Prediction of hepatocellular carcinoma prognosis and immunotherapeutic effects based on tryptophan metabolism-related genes.

Authors:  Chen Xue; Xinyu Gu; Yalei Zhao; Junjun Jia; Qiuxian Zheng; Yuanshuai Su; Zhengyi Bao; Juan Lu; Lanjuan Li
Journal:  Cancer Cell Int       Date:  2022-10-10       Impact factor: 6.429

4.  Dual Effect of Tryptamine on Prostate Cancer Cell Growth Regulation: A Pilot Study.

Authors:  Zhuangzhuang Li; Baoyan Ding; Mustafa R K Ali; Lizhen Zhao; Xiaoling Zang; Zhihua Lv
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

Review 5.  Research progress on microRNA-1258 in the development of human cancer.

Authors:  Mengjia Qian; Yuke Xia; Gong Zhang; Han Yu; Yiyao Cui
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.